Example A — Initial evaluation for urgency and frequency
Clinical: Patient presents with urgency, nocturia, and urinary frequency.
Code(s): Evaluation and management visit.
Dx: N32.81; add symptom codes as documented.

Example B — Diagnostic bladder testing
Clinical: Patient with persistent symptoms undergoes uroflowmetry and post-void residual testing.
Code(s): 51741 – complex uroflowmetry; 51798 – post-void residual (ultrasound, non-imaging).
Dx: N32.81.

Example C — Urodynamic evaluation
Clinical: Persistent incontinence despite medication therapy.
Code(s): 51728 – CMG with voiding pressure study.
Dx: N39.41; N32.81 as additional dx.

Example D — Intravesical Botox® for refractory urge incontinence
Clinical: Refractory urge urinary incontinence after documented failure of 12 weeks of conservative therapy and anticholinergics; 100 units injected.
Code(s): 52287 – cystoscopy with chemodenervation injection; J0585 x units administered/wasted per policy.
Dx: N39.41 urge incontinence (a covered incontinence dx — not N32.81 alone); N32.81 as additional dx.

Example E — PTNS session
Clinical: Weekly posterior tibial nerve stimulation for OAB refractory to medications.
Code(s): 64566 – posterior tibial neurostimulation, percutaneous needle electrode, single treatment.
Dx: N32.81 with the documented incontinence code.

• Objective symptom scale: validated OAB assessment score, repeated over time
• Bladder diary: completed by the patient and filed in the record
• Conservative therapy: behavioral therapy trial with dates; at least 12 weeks documented [VERIFY: LCD timeframe]
• Medication trial: anticholinergic/beta-3 agents tried and failed, or contraindication documented
• UA: current urinalysis
• Updated before each Botox® session: the LCD requires these elements refreshed prior to each treatment [VERIFY: LCD requirement]

• Botox®: drug, total units injected, units wasted, injection sites, cystoscopic findings
• PTNS: session number in the induction/maintenance course and response to date
• SNM: test-phase symptom improvement (diary-documented) supporting permanent implant; programming parameters for 95970–95972

• OAB coded alone for Botox®: carry the specific covered incontinence diagnosis; N32.81 by itself is not covered under the 2026 LCD [VERIFY: LCD].
• Missing conservative-therapy documentation: build the scale/diary/medication-trial elements into intake so every advanced-therapy candidate already has them on file.
• Unit overage: stay within the per-session unit limits for the documented indication; document wastage.
• Prepayment review (WISER): incontinence NCD services in participating states face prior-review or prepayment record review — the NCD requirements apply nationally, so document to them everywhere [VERIFY: WISER states/scope].
• E/M downcoding: document true prescription drug management on medication follow-ups; addenda added after a records request are being dismissed.

• 51741 – Complex uroflowmetry
• 51798 – Post-void residual, ultrasound, non-imaging
• 51726 – Complex cystometrogram
• 51728 – Complex CMG with voiding pressure study
• 51729 – Complex CMG with voiding pressure and urethral pressure profile
• 52000 – Cystourethroscopy (diagnostic)

• 52287 – Cystourethroscopy with injection(s) for chemodenervation of the bladder
• J0585 – Injection, onabotulinumtoxinA, 1 unit — bill actual units administered plus documented wastage per payer policy

• 64566 – Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming

• 64561 – Percutaneous implantation of neurostimulator electrode array, sacral nerve (test stimulation lead)
• 64581 – Open implantation of neurostimulator electrode array, sacral nerve
• 64590 – Insertion or replacement of peripheral/sacral neurostimulator pulse generator or receiver
• 64585 – Revision or removal of peripheral neurostimulator electrode array
• 64595 – Revision or removal of peripheral/sacral neurostimulator pulse generator or receiver
• 95970–95972 – Electronic analysis of implanted neurostimulator, without and with (simple/complex) programming

• N32.81 – Overactive bladder
• N39.41 – Urge incontinence
• N39.42 – Incontinence without sensory awareness
• N39.43 – Post-void dribbling
• N39.45 – Continuous leakage
• N39.46 – Mixed incontinence
• N39.490 – Overflow incontinence
• N39.492 – Postural (urinary) incontinence
• N39.498 – Other specified urinary incontinence
• N39.3 – Stress incontinence (female) (male) — code also any associated OAB (N32.81)
• R32 – Urinary incontinence, unspecified — avoid when a specific type is documented
• R35.0 – Urinary frequency; R35.1 – Nocturia
• Neurogenic: N31.1 reflex neuropathic bladder, N31.2 flaccid neuropathic bladder, N31.8 other neuromuscular dysfunction, N31.9 unspecified

Tip: ICD-10 instructs "code also any associated overactive bladder (N32.81)" with the N39.3/N39.4- incontinence codes — report both, and sequence the specific incontinence code first when a coverage policy keys on it. Avoid unspecified codes (R32) when the note supports a specific type.

• Symptom characterization: urgency, frequency, nocturia, leakage type; validated symptom scale scores
• Treatment pathway: behavioral therapy and medication trials with dates, response, and side effects
• Bladder diary: on file and referenced in the plan
• Medical necessity for each escalation: why the next therapy step is required now
• Per-session reassessment: updated symptom scores and necessity documentation before each Botox® session
• Prescription drug management: drug, dose, risk/benefit discussion, and continuation decision documented at medication follow-ups

• -25 for a significant, separately identifiable E/M on the same day as a procedure (e.g., PTNS or injection visit). Watch item: the CY2027 PFS proposed rule would pay only the highest-valued service on the day at 100% and reduce the E/M (or the lower-valued procedure) by 50% [VERIFY: proposed rule — not final].
• JW/JZ drug wastage modifiers on J0585 per payer policy [VERIFY: payer wastage policy].

• 52287 and 64566: 0-day global. 64561 and 64590: 10-day global. 64581: 90-day global.
• Confirm using your MAC/payer fee schedule.

• NCDs: Medicare national coverage determinations govern sacral neuromodulation and incontinence devices — their documentation requirements apply nationally.
• WISER program: incontinence NCD services in participating states are subject to voluntary prior authorization or prepayment record review; expect expansion [VERIFY: current WISER states].
• 2026 Botox® LCD/LCA: see the Coding Update on the Facility Coding tab for covered diagnoses, unit limits, and documentation requirements.
• 2027 proposed: urodynamics payment is projected to drop under the proposed practice-expense methodology changes; the bulking-agent code 51715 would gain the agent's invoice cost as a direct expense [VERIFY: proposed rule — not final].

• Facility charge capture: same CPT® codes as the physician side — 52287 (Botox® injection), 64566 (PTNS), 64561/64581/64590 (SNM), urodynamics 51726–51729.
• Drugs: J0585 units administered plus documented wastage; packaging status differs by setting.
• Devices: SNM implants are device-intensive — capture the device and confirm the OPPS/ASC device offset rules [VERIFY: device-intensive status].
• CDM mapping: confirm chargemaster lines for neurostimulator programming (95970–95972) map to the service actually performed.

• N32.81 – Overactive bladder (additional dx, not stand-alone for Botox®)
• N39.41 – Urge incontinence
• N39.46 – Mixed incontinence
• N39.490 – Overflow incontinence
• N31.1–N31.9 – Neurogenic bladder codes for neurogenic detrusor overactivity

Facility tip: the covered diagnosis under the Botox® LCD must appear on the facility claim exactly as supported by the record — align dx selection and sequencing with the professional claim.

• Pre-treatment file: symptom scale, bladder diary, conservative/medication-trial history available in the facility record before advanced therapy
• Drug documentation: units administered, units wasted, lot documentation per pharmacy policy
• Device documentation: implant details for SNM cases, including test-phase response supporting the permanent implant
• Record alignment: op/procedure note, nursing record, medication administration record, supply log, and charge capture must tell the same story

• Packaging rules vary: drug and supply packaging differ between office, ASC, and HOPD settings.
• Site-of-service variance: Botox® and PTNS are commonly office-based; SNM implant staging spans office/ASC/HOPD — confirm coverage and payment by setting.
• Prepayment review readiness: in WISER states, expect records to be pulled before payment on incontinence NCD services — have the coverage documentation assembled at charge entry, not after denial [VERIFY: WISER scope].